Pfizer
Pfizer and Eli Lilly defeat lawsuit over claims Viagra and Cialis cause cancer
April 9, 2020Business Services Pfizer, viagra
Pfizer and Eli Lilly have defeated a class action lawsuit seeking billions in damages over claims that Viagra and Cialis …
Pfizer scores EU approval for MabThera biosimilar Ruxience
April 6, 2020Sales and Marketing MabThera, Pfizer, Ruxience, biosimilar
The European Commission has moved to authorise Ruxience, Pfizer’s biosimilar version of MabThera (rituximab). The decision marks the seventh biosimilar …
Bavencio Phase 3 head and neck cancer trial terminated
March 16, 2020Research and Development, Sales and Marketing Bavencio, Cancer, EMD Serono, Merck KGaA, Pfizer, trial failure
Merck KGaA, its biopharma division EMD Serono, and Pfizer have announced their decision to terminate their ongoing Phase 3 trial …
Europe approves first treatment for transthyretin amyloidosis in cardiomyopathy patients: Pfizer’s Vyndaqel
February 19, 2020Research and Development, Sales and Marketing Europe, Pfizer, Vyndaqel, pharma, transthyretin amyloidosis
The European Commission (EC) has awarded marketing approval to Pfizer’s Vyndaqel (tafamidis), it has emerged, for the treatment of wild-type …
Europe’s CHMP recommends Pfizer’s biosimilar of Roche’s MabThera
February 4, 2020Manufacturing and Production, Sales and Marketing MabThera, Pfizer, Ruxience, biosimilar, pharma
The EMA’s Committee for Medicinal Products for Human Use (CHMP) has revealed that it has awarded a positive opinion for …
Pfizer’s Ibrance combo authorised via the Cancer Drugs Fund for advanced breast cancer
January 15, 2020Research and Development Cancer Drugs Fund, NICE, Pfizer, ibrance, pharma
NICE, the drug watchdog for England and Wales, has given its approval for Pfizer’s Ibrance (palbociclib) in combination with AstraZeneca’s …
Biogen picks up Pfizer’s Phase 1 therapy for Alzheimer’s symptoms in potential $700m deal
January 14, 2020Manufacturing and Production, Sales and Marketing Alzheimer's, Biogen, Pfizer, pharma
Biogen has entered into an agreement with Pfizer to acquire the latter’s Phase 1 candidate PF-05251749 in order to develop …
Bavencio extends survival at Phase 3 in previously untreated locally advanced or metastatic urothelial carcinoma
January 7, 2020Manufacturing and Production, Research and Development Bavencio, Merck KGaA, Pfizer, pharma
Bavencio (avelumab), the anti-programmed death ligand-1 (PD-L1) antibody co-developed by Pfizer and Merck KGaA’s biopharma unit EMD Serono, has been …
FDA approves Pfizer and Astellas Pharma’s prostate cancer drug
December 17, 2019Manufacturing and Production Astellas Pharma, Cancer, FDA, Pfizer, Xtandi, prostate cancer
The FDA has approved Pfizer and Astellas Pharma’s Xtandi (enzalutamide) to treat patients with a type of prostate cancer. The …
Pfizer’s Vyndaqel scores CHMP support for transthyretin amyloidosis in cardiomyopathy patients
December 16, 2019Sales and Marketing Pfizer, Vyndaqel, pharma
Pfizer’s once-daily 61mg oral capsule formulation of Vyndaqel (tafamidis) has secured a positive opinion from the European Medicines Agency’s (EMA) …
Pfizer and Sangamo’s haemophilia gene therapy shows increased factor VIII levels
December 9, 2019Manufacturing and Production, Sales and Marketing American Society of Hematology, Pfizer, Sangamo Therapeutics, hematology
Pfizer and Sangamo Therapeutics have revealed that their investigational gene therapy, SB-525, sustained increased factor VIII (FVIII) levels in patients …
Pfizer’s Ibrance approved by NICE, to be added to the Cancer Drugs Fund
November 28, 2019Manufacturing and Production, Research and Development Cancer Drugs Fund, NHS, NICE, Pfizer, breast cancer, ibrance, pharma
Today it was announced that the National Institute for Health and Care Excellence (NICE) has recommended Pfizer’s Ibrance (palbociclib) to …
New ICER report reveals most cost-effective rheumatoid arthritis therapies
November 27, 2019Research and Development, Sales and Marketing AbbVie, Eli Lilly, Humira, Olumiant, Pfizer, Rinvoq, Xeljanz, pharma
The Institute for Clinical and Economic Review (ICER) has unveiled a new report comparing the clinical efficacy and cost-effectiveness of …
Pfizer’s Humira biosimilar secures FDA approval, due to launch in 2023
November 18, 2019Sales and Marketing Abrilada, FDA, Humira, Pfizer, biosimilar, pharma
Pfizer has confirmed the FDA approval of Abrilada (adalimumab-afzb), its biosimilar version of AbbVie’s Humira, the world’s best-selling drug, …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
